Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25605581 | 1.00 | OPRL1 (0.40) | OPRL1OPRM1OPRK1CHRM2CHRM1 | |
| SCHEMBL24838380 | 0.91 | CHRM1 (0.43) | OPRL1OPRM1OPRK1CHRM2CHRM1 | |
| SCHEMBL25605709 | 0.91 | CHRM1 (0.43) | OPRL1OPRM1OPRK1CHRM2CHRM1 | |
| SCHEMBL25604713 | 0.85 | OPRL1 (0.41) | OPRL1OPRM1OPRK1CHRM2CHRM1 | |
| SCHEMBL25630791 | 0.83 | CHRM1 (0.41) | OPRL1OPRM1OPRK1CHRM2CHRM1 | |
| SCHEMBL25605587 | 0.82 | EPHX2 (0.45) | CHRM2CHRM1MBTD1L3MBTL3CYP3A4 | |
| SCHEMBL24838461 | 0.82 | LMNA (0.47) | OPRL1OPRM1CHRM2CHRM1CYP3A4 | |
| SCHEMBL25600507 | 0.82 | OPRL1 (0.34) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL25600504 | 0.82 | OPRL1 (0.34) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL25107536 | 0.82 | MEN1 (0.46) | CHRM2CHRM1MBTD1L3MBTL3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885OPRK1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.